CONITEC advises the MoH regarding the reimbursement of new products. CONITEC is not able to assess all new drugs and therefore only assesses those which have been requested for a review by various stakeholders (such as manufacturers, patient associations and the MoH). The HTA evaluation takes into account he costs and benefits of a new product. An ICER of the product must be submitted, although there no set cost-effectiveness thresholds for decision making in place. Products can either be recommended, restricted or excluded/withdrawn from RENAME. Reimbursement of orphan drugs may be challenging as there are no orphan drug specific programs in place (e.g. early access, funding).